Abstract Number: 2236 • 2016 ACR/ARHP Annual Meeting
Effects of Repository Corticotropin Injection on Medication Use in Patients with Rheumatologic Conditions: A Claims Data Study
Background/Purpose: Repository corticotropin injection (RCI) may produce anti-inflammatory and immune-modulatory effects. This study examined the demographics of those who used RCI and the trends in…Abstract Number: 2237 • 2016 ACR/ARHP Annual Meeting
Biologic DMARD Use Among U.S. Patients in an Online Rheumatoid Arthritis Community
Background/Purpose: Multiple biologic DMARDs (bDMARDs) are approved in the US for the treatment of RA. Previous studies have indicated significant clinical inertia in moving patients…Abstract Number: 2238 • 2016 ACR/ARHP Annual Meeting
RA Medication Preferences Among U.S. Patients in an Online Rheumatoid Arthritis Community
Background/Purpose: Medications used to manage RA vary in efficacy, safety, and convenience of use. A better understanding of patient preferences of these attributes is key…Abstract Number: 2239 • 2016 ACR/ARHP Annual Meeting
Patterns of Abatacept Utilization in Patients with Rheumatoid Arthritis. Have the Baseline Characteristics of These Patients Changed over Time?
Background/Purpose: Abatacept (ABA), a T cell co-stimulation inhibitor, was initially approved by the European Medicine Agency (EMA) for patients with rheumatoid arthritis (RA) who had…Abstract Number: 2240 • 2016 ACR/ARHP Annual Meeting
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Background/Purpose: This study examined treatment patterns in a rheumatology patient (pt) population initially prescribed innovator infliximab (IFX) that either switched to biosimilar infliximab (CT-P13) or…Abstract Number: 2241 • 2016 ACR/ARHP Annual Meeting
Health Economics of Uncontrolled Gout in the United States: A Systematic Literature Review
Background/Purpose: Gout is a crystal deposition disease and the most prevalent inflammatory arthritis in the United States (US). Maintaining gout control has been associated with…Abstract Number: 2242 • 2016 ACR/ARHP Annual Meeting
Comparison of Assessment and Management of RA and Other Rheumatic Diseases By Rheumatologists in Private Practices or an Academic Medical Center
Background/Purpose: Since 80% of rheumatologists practice outside the university setting, training projects for rheumatoid arthritis (RA) may benefit from an improved understanding of RA management…Abstract Number: 2243 • 2016 ACR/ARHP Annual Meeting
The Paucity of the Evidence Base for American College of Rheumatology Practice Guidelines
Background/Purpose: The American College of Rheumatology (ACR) practice guidelines establish U.S. and international treatment recommendations and hence performance measures and research priorities, so we sought…Abstract Number: 2244 • 2016 ACR/ARHP Annual Meeting
Utilization Patterns of Subcutaneously Administered Biologic Medications within a Sample of Rheumatoid Arthritis Patients
Background/Purpose: Adherence to medication is crucial to the maximum therapeutic benefit of biologic treatment. The plethora of currently approved biologic agents makes comparison…Abstract Number: 2245 • 2016 ACR/ARHP Annual Meeting
Injectable Corticosteroid Use in Musculoskeletal Care Specialties
Background/Purpose: Injectable corticosteroids (IC) are widely used for joint and soft tissue injections. Although four main types of preparations are available, there is sparse evidence…Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting
Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?
Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…Abstract Number: 2247 • 2016 ACR/ARHP Annual Meeting
REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
Background/Purpose: Rheumatoid Arthritis (RA) has differing therapeutic outcomes, with resulting differences in function and quality of life. Little is known about the effects of disease…Abstract Number: 2248 • 2016 ACR/ARHP Annual Meeting
The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis
Background/Purpose: In the pre-biologic era, major costs faced by patients with RA included hospitalization and joint replacement. Biologic agent development has led to increasing outpatient…Abstract Number: 2249 • 2016 ACR/ARHP Annual Meeting
Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Background/Purpose: While difficult to directly compare effectiveness of biologics in observational settings, drug discontinuation can be a useful substitute. We compared the discontinuation rates of…Abstract Number: 2250 • 2016 ACR/ARHP Annual Meeting
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Background/Purpose: Advanced therapies including bDMARDs and tofacitinib have been shown to help control disease progression in rheumatoid arthritis (RA) and reduce joint damage. The aim…
ACR Meeting Abstracts